May 15, 2025
Emmaus Life Sciences Reports Quarterly Financial Results
Apr 14, 2025
Emmaus Life Sciences Reports 2024 Financial Results
Jan 29, 2025
Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia
Sep 10, 2024
Emmaus Life Sciences Reports Quarterly Financial Results
Feb 02, 2024
Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico
Jan 27, 2021
Emmaus Life Sciences Reports Increase in Sales Volume in 2020
Dec 03, 2020
Endari® Granted Orphan Drug Status in Switzerland
Nov 10, 2020
Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari®
Nov 03, 2020
FDA Approves Updated Label for Endari®
Oct 14, 2020
Emmaus Life Sciences Announces the Sale of its Telcon RF Pharmaceutical Inc. Shares
Sep 26, 2019
Emmaus Life Sciences Announces its Common Stock to Begin Trading on OTCQB September 26
Sep 19, 2019
Emmaus Life Sciences Announces Withdrawal of Marketing Authorization Application to European Medicines Agency
Sep 10, 2019
Emmaus Life Sciences to be Delisted from Nasdaq Stock Market Following Hearing
Sep 03, 2019
Emmaus Life Sciences Granted European Patent for use of Pharmaceutical-grade L-glutamine in Treating Diverticulosis
Aug 28, 2019
Emmaus Life Sciences Adds Oncology Supply as Distributor
Aug 14, 2019
Emmaus Life Sciences to Host "Sideline Sickle Cell" Community Town Hall with ASAP and FSCDR in South Florida
Aug 08, 2019
Emmaus Life Sciences Reiterates Financial Benefits from Recent Merger
Jul 29, 2019
Emmaus Life Sciences Details Financial Benefits from Recent Merger, including Improved Balance Sheet and Reduced Debt Service
Jul 24, 2019
Emmaus Life Sciences Brings "Sideline Sickle Cell" Campaign to Dallas for Participation in Annual Warriors Convention
Jul 08, 2019
Emmaus Life Sciences Announces Initiation of its Diverticulosis Study